Compile Data Set for Download or QSAR
maximum 50k data
Found 32 Enz. Inhib. hit(s) with all data for entry = 7716
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102350(US10562854, No. F3 | US8536181, F3 | US9278930, F3)
Affinity DataIC50:  1.20E+3nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102349(US10562854, No. E33 | US8536181, E33 | US9278930, ...)
Affinity DataIC50:  2.10E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102345(US10562854, No. D10 | US8536181, D10 | US9278930, ...)
Affinity DataIC50:  4.40E+3nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102351(US10562854, No. F2 | US8536181, F2 | US9278930, F2)
Affinity DataIC50:  5.00E+3nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102350(US10562854, No. F3 | US8536181, F3 | US9278930, F3)
Affinity DataIC50:  7.40E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM126621(US10562854, No. B5 | US8778412, B5 | US9278930, B5)
Affinity DataIC50:  9.00E+3nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102336(US10562854, No. C17 | US8536181, C17 | US9278930, ...)
Affinity DataIC50:  1.10E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102341(US10562854, No. B14 | US8536181, B14 | US9278930, ...)
Affinity DataIC50:  1.10E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102342(US10562854, No. C19 | US8536181, C19 | US9278930, ...)
Affinity DataIC50:  1.20E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102337(US10562854, No. C35 | US8536181, C35 | US9278930, ...)
Affinity DataIC50:  1.20E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US10562854, No. C14 | US8536181, C14 | US9278930, ...)
Affinity DataIC50:  1.20E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102346(US10562854, No. D14 | US8536181, D14 | US9278930, ...)
Affinity DataIC50:  1.20E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102347(US10562854, No. C1 | US8536181, C1 | US9278930, C1)
Affinity DataIC50:  1.20E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US10562854, No. B9 | US8536181, B9 | US9278930, B9)
Affinity DataIC50:  1.26E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.40E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102340(US10562854, No. C33 | US8536181, C33 | US9278930, ...)
Affinity DataIC50:  1.60E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.66E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102343(US10562854, No. B9 | US8536181, B9 | US9278930, B9)
Affinity DataIC50:  1.70E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102344(US10562854, No. A18 | US8536181, A18 | US9278930, ...)
Affinity DataIC50:  1.80E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102346(US10562854, No. D14 | US8536181, D14 | US9278930, ...)
Affinity DataIC50:  1.90E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US10562854, No. C14 | US8536181, C14 | US9278930, ...)
Affinity DataIC50:  2.06E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102349(US10562854, No. E33 | US8536181, E33 | US9278930, ...)
Affinity DataIC50:  2.10E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102345(US10562854, No. D10 | US8536181, D10 | US9278930, ...)
Affinity DataIC50:  2.70E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102336(US10562854, No. C17 | US8536181, C17 | US9278930, ...)
Affinity DataIC50:  2.74E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102344(US10562854, No. A18 | US8536181, A18 | US9278930, ...)
Affinity DataIC50:  2.92E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102347(US10562854, No. C1 | US8536181, C1 | US9278930, C1)
Affinity DataIC50:  4.20E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102337(US10562854, No. C35 | US8536181, C35 | US9278930, ...)
Affinity DataIC50:  4.25E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM126621(US10562854, No. B5 | US8778412, B5 | US9278930, B5)
Affinity DataIC50:  5.30E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102340(US10562854, No. C33 | US8536181, C33 | US9278930, ...)
Affinity DataIC50:  5.30E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102342(US10562854, No. C19 | US8536181, C19 | US9278930, ...)
Affinity DataIC50:  6.29E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102341(US10562854, No. B14 | US8536181, B14 | US9278930, ...)
Affinity DataIC50:  7.80E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102351(US10562854, No. F2 | US8536181, F2 | US9278930, F2)
Affinity DataIC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent